- Lilly makes up to $3.8B psychedelics play in AtaiBeckley takeoverWith the AtaiBeckley acquisition, Eli Lilly is jumping into psychedelics, a drug class that Jefferies analysts say could herald the “biggest change” for the field of psychiatry.BioSpace · 12d ago↗ source
- Merck wins first approval of a PCSK9 cholesterol pillThe speedy clearance of Lipfendra is an important milestone for Merck and the result of a controversial voucher program put in place by former FDA commissioner Marty Makary.BioPharma Dive · 12d ago↗ source
- Merck dives into cholesterol with first FDA approval for oral PCSK9 inhibitorMerck’s once-daily pill is the first oral PCSK9 inhibitor to hit the market for high cholesterol, beating AstraZeneca in the race to develop more accessible treatment options.